Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

VioQuest Completes Merger with Greenwich Therapeutics; Acquires Oncology Compounds

By Pharmaceutical Processing | October 19, 2005

VioQuest Pharmaceuticals, Inc.recently completed its acquisition of Greenwich Therapeutics, which owned the exclusive rights to two anti-cancer compounds that provide a targeted approach to the treatment of ovarian, breast, pancreatic, melanoma, myeloma, and renal cancers:

VQD-001 — Sodium Stibogluconate (SSG), targets a class of enzymes, protein tyrosine phosphatases, in cells that may play a significant role in certain types of cancer. SSG recently entered a Phase I clinical trial at the Cleveland Clinic Cancer Center to examine the effectiveness, safety and tolerability of SSG for the treatment of solid tumors, lymphoma and myeloma.

VQD-002 — Triciribine (TCN-P), a tricyclic nucleoside currently being developed at the Moffitt Cancer Center, University of South Florida, has been shown in preclinical studies to significantly inhibit tumor growth associated with Akt over-expression, which often occurs in breast, ovarian, colorectal and other cancers.

“With the acquisition of these two promising oncology compounds and net proceeds from the private placement, we are well positioned to aggressively drive the further clinical development of our therapeutics pipeline,” commented Daniel Greenleaf. “Based on the strong body of preclinical data, we are very hopeful about the potential of both drug candidates to serve a tremendous need in the oncology market and look forward to continuing their respective clinical programs with two renowned cancer research centers, the Cleveland Clinic Cancer Center in Ohio and Moffitt Cancer Center in Florida.”

In addition, prior to the acquisition of Greenwich, VioQuest completed its reincorporation under Delaware law, which was approved by VioQuest’s shareholders at a special meeting held on October 6, 2005.

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards